The association between ANKH promoter polymorphism and chondrocalcinosis is independent of age and osteoarthritis : results of a case–control study by Abhishek, Abhishek et al.
 http://wrap.warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
Original citation: 
Abhishek, Abhishek, Doherty, Sally, Maciewicz, Rose, Muir, Kenneth (Kenneth R.), 
Zhang, Weiya, Doherty, Michael and Valdes, Anna M.. (2014) The association between 
ANKH promoter polymorphism and chondrocalcinosis is independent of age and 
osteoarthritis: results of a case–control study. Arthritis Research & Therapy, Volume 16 
(Number 1). Article number R25. ISSN 1478-6354 
 
Permanent WRAP url: 
http://wrap.warwick.ac.uk/60179         
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 2.0 Generic (CC 
BY 2.0) license and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/2.0/ 
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may 
be cited as it appears here. 
 
For more information, please contact the WRAP Team at: publications@warwick.ac.uk  
RESEARCH ARTICLE Open Access
The association between ANKH promoter
polymorphism and chondrocalcinosis is
independent of age and osteoarthritis: results of
a case–control study
Abhishek Abhishek1,2*, Sally Doherty2, Rose Maciewicz3, Kenneth Muir4, Weiya Zhang2, Michael Doherty2
and Anna M Valdes2
Abstract
Introduction: Chondrocalcinosis (CC) most commonly results from calcium pyrophosphate crystal deposition
(CPPD). The objective of this study is to examine the association between candidate single-nucleotide polymorphisms
(SNPs) and radiographic CC.
Methods: SNPs in ankylosis human (ANKH), high ferritin (HFE), tissue non-specific alkaline phosphatase (TNAP),
ecto-neucleotide pyrophosphatase 1 (ENPP1), and transferrin (TE) genes were genotyped in participants of the Genetics
of Osteoarthritis and Lifestyle (GOAL) and Nottingham Osteoarthritis Case-Control studies. Adjusted genotype odds ratio
(aORGENOTYPE), the OR for association between one additional minor allele and CC, was calculated and adjusted for age,
gender, body mass index (BMI), and osteoarthritis (OA) by using binary logistic regression. Statistical significance was set
at P ≤0.003 after Bonferroni correction for multiple tests.
Results: The -4bpG > A polymorphism in the 5′ untranslated region (5′ UTR) of ANKH associated with CC after Bonferroni
correction. This was independent of age, gender, OA, and BMI; aORGENOTYPE (95% confidence interval, or CI) was 1.39
(1.14-1.69) (P = 0.001). rs3045 and rs875525, two other SNPs in ANKH, associated with CC; aORGENOTYPE (95% CI) values
were 1.31 (1.09-1.58) (P = 0.005) and 1.18 (1.03-1.35) (P = 0.015), respectively; however, this was non-significant after
Bonferroni correction.
Conclusions: This study validates the association between a functional polymorphism in the 5′ UTR of ANKH and CC
and shows for the first time that this is independent of age and OA – the two key risk factors for CC. It shows that other
SNPs in ANKH may also associate with CC. This supports the role of extracellular inorganic pyrophosphate in the
pathogenesis of CC. The findings of this hospital-based study require replication in a community-based population.
Introduction
Chondrocalcinosis (CC) most commonly results from cal-
cium pyrophosphate (CPP) crystal deposition (CPPD) [1].
CPPD may present as acute CCP crystal arthritis, CPPD
with osteoarthritis (OA), chronic CPP crystal inflammatory
arthritis, or asymptomatic CC [1]. Age, OA, diuretic use,
and joint injury are recognized risk factors for CC [1,2].
Additionally, metabolic diseases that elevate extracellular
pyrophosphate (ePPi) levels (hyperparathyroidism, hypo-
magnesemia, and hypophosphatasia), hemochromatosis,
and familial predisposition are uncommon risk factors
[1,2]. Though rare, familial predisposition is reported from
several countries and different ethnic groups [3-9]. The
pattern of inheritance is usually autosomal dominant. The
main clinical phenotype is characterized by early onset (in
the 20s or 30s) of acute CPP crystal arthritis with florid
polyarticular CC and variable severity of accompanying
structural arthritis/OA. However, a second phenotype with
later onset in the sixth to seventh decades and oligo-
articular CC that more closely resembles sporadic CPPD
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has also been reported [10]. This latter familial form may
be more common than is recognized, the late onset of
disease expression and geographic dispersal of families
tending to mask such predisposition. An association with
benign childhood fits appears unique to one UK family
with early-onset polyarticular CC, and the responsible
gene—CC gene 2 (CCAL2) on chromosome 5p15—was
first identified in this family [11]. Other kindreds with CC
due to mutations at this locus [3] have been reported, and
the responsible gene was subsequently identified as the
ankylosis human (ANKH) gene [12]. The other reported
locus in an American family with premature OA and asso-
ciated CPPD (CCAL1) is on chromosome 8q [13], and a
specific gene predisposing to CPPD at this site has not
been identified.
Although several kindreds with familial CPPD are re-
ported, the evidence for genetic contribution to sporadic
CC is conflicting [3]. For example, the -4bpG > A transi-
tion in the 5′ untranslated region (5′ UTR) of ANKH
(which encodes the trans-membrane PPi transport protein
ANKH) associated with CC in a study of 128 CC cases
and 475 healthy controls [14], whereas hereditary contri-
bution to CC was not detected in a larger sibling study
(n = 1,841) [15]. Therefore, the objectives of this study
were to validate the reported association between -4bpG >
A transition in the 5′ UTR of ANKH and CC, to examine
whether this is independent of other risk factors of CC such
as age and OA, and to investigate whether other candidate
single-nucleotide polymorphisms (SNPs) in genes involved
in PPi metabolism—ANKH, tissue non-specific alkaline
phosphatase (TNAP), and ectonucleotide pyrophosphatase
1 (ENPP1) (Figure 1)—or iron overload (for example, high
ferritin and transferrin) associate with CC.
Methods
Study design and participants
The case-control study used data from the Genetics of
Osteoarthritis and Lifestyle (GOAL) and Nottingham
Osteoarthritis Case-Control (NOAC) studies [16,17]
(Table 1). The GOAL study was approved by the Not-
tinghamshire Research Ethics Committee (UK). The
NOAC study was approved by the North Nottingham-
shire Research Ethics Committee and the Leicestershire,
Northamptonshire, and Rutland Research Ethics Com-
mittee. All study participants gave written informed
consent. These studies, originally set up to examine the
genetics of large-joint OA, recruited Caucasians with
(a) hip or knee OA severe enough to require joint re-
placement surgery or (b) no radiographic or clinical fea-
tures of hip or knee OA [16,17]. All participants were
Figure 1 Extracellular pyrophosphate metabolism. ANKH, (progressive) ankylosis human; Mg++, magnesium; NTP, nucleotide tri-phosphate;
PC1, plasma cell glycoprotein 1; Pi, phosphate; PPi, pyrophosphate; TNAP, tissue non-specific alkaline phosphatase.
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residents of Nottinghamshire, UK. Information about dis-
ease and demographic variables were collected at the study
visit. Genomic DNA was extracted from the peripheral
blood leukocytes by using standard protocols. GOAL study
participants had radiographs of hands, knees, and pelvis;
and the NOAC study participants had radiographs of the
index knee or hip joint awaiting replacement. These radio-
graphs were scored for CC at the knees, hips, wrists, and
symphysis pubis and for metacarpophalangeal joint (MCPJ)
calcification by a single trained observer (Sally Doherty).
Cases and controls
Cases were participants with CC at any joint, whereas
controls did not have CC at any joint x-rayed.
Single-nucleotide polymorphism selection
Seventeen SNPs were selected on the basis of published
associations with various phenotypes (Table 2).
Genotyping
Genotyping was carried out at AstraZeneca laboratories in
Macclesfield, UK, by using the Taqman method and at
Kbioscience Ltd (Hertfordshire, UK) by using the Kompe-
titive Allele Specific PCR (KASPar) chemistry. All 17 SNPs
were genotyped in the GOAL study. All selected SNPs in
any gene which contained at least one SNP that associated
with CC with an uncorrected P ≤0.10 in the GOAL study
were genotyped in the NOAC study participants.
Covariates
Data about age (years), height (centimeters), and weight
(kilograms) were collected at the study visit. Height and
weight were used to calculate body mass index (BMI)
(kg/m2). OA was defined as knee or hip OA clinically se-
vere enough to warrant consideration of joint replace-
ment surgery.
Table 1 Demographics of study participants
CC present CC absent
n = 658 n = 4,283 P
Age in years, mean (SD) 70.89 (8.09) 67.58 (8.58) <0.001
Female gender, number (percentage) 325 (49.4%) 2,240 (52.3%) 0.165
Body mass index in kg/m2, mean (SD) 28.52 (4.83) 29.48 (5.47) <0.001
Knee or hip OA, number (percentage) 584 (90.0%) 3,378 (79.0%) <0.001
CC, chondrocalcinosis; OA, osteoarthritis; SD, standard deviation.
Table 2 Association between all single-nucleotide polymorphisms and chondrocalcinosis in the Genetics of Osteoarthritis
and Lifestyle study
SNP Reason for selection (association with): Minor allele frequency, % ORGENOTYPE
(95% CI)
P
CC + CC −
ANKH −4bpG > A 5′ UTR Chondrocalcinosis [14] 11.0 8.2 1.36 (1.07-1.73) 0.013
rs3045 Rotator cuff tear and low intracellular PPi [18] 12.7 10.1 1.28 (1.02-1.60) 0.030
rs39968 Parathyroid hormone level [19] 28.1 30.9 0.89 (0.76-1.05) 0.160
rs875525 Parathyroid hormone level [19] 28.1 25.6 0.89 (0.76-1.04) 0.152
HFE rs1800562 Hemochromatosis [20,21] 7.8 7.8 1.01 (0.77-1.33) 0.937
rs1799945 Hemochromatosis [20,21] 17.1 14.7 1.20 (0.99-1.46) 0.070
TNAP rs3200254 Increased TNAP activity [22] 11.1 11.0 0.99 (0.79-1.25) 0.957
rs4654760 Rotator cuff tear [18] 6.7 6.6 1.01 (0.76-1.35) 0.955
ENPP1 rs1044498 Osteoarthritis [23] 13.7 12.5 1.07 (0.86-1.32) 0.564
rs28933977 Osteoarthritis [23] 3.7 4.1 0.81 (0.55-1.20) 0.826
rs1800949 Osteoarthritis [23] 25.7 26.2 0.98 (0.83-1.16) 0.298
rs858342 Osteoarthritis [23] 24.1 25.1 0.92 (0.78-1.10) 0.365
rs943003 Obesity [24] 40.6 41.9 1.06 (0.86-1.32) 0.401
Transferrin rs1799852 Iron overload [25] 8.2 9.4 0.89 (0.69-1.15) 0.372
rs2280673 Iron overload [25] 34.7 35.4 0.97 (0.83-1.12) 0.664
rs3811647 Iron overload [25] 36.5 34.7 1.08 (0.92-1.26) 0.348
5′ UTR, 5′ untranslated region; ANKH, ankylosis human; CC, chondrocalcinosis; CI, confidence interval; ENPP1, ecto-neucleotide pyrophosphatase 1; HFE, high
ferritin; ORGENOTYPE, genotype odds ratio; PPi, pyrophosphate; SNP, single-nucleotide polymorphism; TNAP, tissue non-specific alkaline phosphatase.
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Statistical analysis
Mean and standard deviation (SD) and number (percent-
age) were used for descriptive purposes. Chi-square test
and student t test were used to compare categorical and
continuous variables. Cases with CC were compared with
controls without CC. All SNPs were checked for Hardy-
Weinberg equilibrium (HWE). Data from the GOAL and
NOAC studies were pooled together for analyzing genetic
risk. Genotype odds ratio (ORGENOTYPE)—the OR for as-
sociation between increasing number of minor alleles of
an SNP and CC—was calculated. Binary logistic regression
was used to calculate aORGENOTYPE (95% confidence
interval, or CI) adjusting for age (tertiles), gender, BMI
(tertiles), and OA. Additionally, ORGENOTYPE was meta-
analyzed with published studies by using fixed effects ana-
lysis given the lack of heterogeneity between studies.
Meta-analyses were performed by using R V.2.13.1 [26].
Other analyses were carried out by using SPSSv14.
Statistical significance for genetic association was set at
P ≤0.003 after application of Bonferroni correction for
multiple tests. Linkage disequilibrium for the four ANKH
SNPs studied was estimated from unphased genotype data
by using the Haploview 4.2 version [27].
Results and discussion
The descriptive characteristics of study participants are
presented in Table 1. Three thousand one hundred forty-
one GOAL and 1,800 NOAC study participants were in-
cluded. The mean age (SD), number of females (percent-
age), and mean BMI (SD) of the GOAL study and NOAC
study participants were 66.6 (7.9) and 70.5 (9.2) years,
1,520 (48.4%) and 1,045 (58.1%) women, and 29.3 (5.3) and
29.5 (5.6) kg/m2, respectively. GOAL study participants
were significantly younger (P <0.001), were less likely to be
female (P <0.001), and had similar BMI (P = 0.22) com-
pared with the NOAC study participants.
Six hundred fifty-eight (13.2%) participants had CC at
any site. All genotyped SNPs were in HWE. As TNAP571
[28] was a rare mutation in the GOAL study population
(minor allele frequency = 0.01), it was excluded from fur-
ther analysis. Three ANKH and one HFE SNPs associated
with CC with an uncorrected P ≤0.10 in the GOAL study
population (Table 2). Thus, all ANKH (−4bpG > A 5′ UTR,
rs3045, rs39968, and rs875525) and HFE (rs1800562 and
rs1799945) SNPs genotyped in the GOAL study were fur-
ther genotyped in the NOAC study participants. The four
ANKH SNPs were not in linkage disequilibrium (Table 3).
Among the six SNPs genotyped in both the GOAL and
NOAC studies, the -4bpG > A 5′ UTR of ANKH associated
with CC after adjustment for age, gender, BMI, and OA;
aORGENOTYPE was 1.39 (1.14-1.69) (P = 0.001) (Table 4).
There was a trend toward an association between rs3045
and CC; aORGENOTYPE was 1.31 (1.09-1.58) (P = 0.005);
however, it was not statistically significant after application
of Bonferroni correction (Table 4). The frequency of rare
and common allelic variants in the ANKH and HFE SNPs
genotyped in both the GOAL and NOAC studies is shown
in an additional file (Additional file 1: Table S1).
Comparison with published studies
Two studies have reported on the association between
CC and HFE SNPs [20,21]. Of these, one study reported
genotype data about rs1800562, and rs1799945 without
reporting full data on compound heterozygote numbers
[20], whereas the other did not report detailed genotype
data [21]. Therefore, the latter study was not included in
the meta-analysis. In a meta-analysis of the data of the
present study and of the study by Alizadeh et al. [20],
the values for pooled ORGENOTYPE (95% CI) for associ-
ation between rs1799945 and rs1800562 and CC were
1.20 (1.04-1.39) (P = 0.015) and 1.08 (0.88-1.33) (P =
0.445), respectively. Similarly, the results of the present
study and the previous study that reported an associ-
ation between CC and -4bpG > A transition in the 5′
UTR of ANKH were meta-analyzed [14]. The pooled
ORGENOTYPE (95% CI) was 1.36 (1.13-1.61) (P = 0.001).
The present study confirms the association between CC
and -4bpG > A transition in the 5′ UTR of ANKH. It is
the first study to show that this association is independent
of age and OA, which are the two major established risk
factors of CC. This study also raises the possibility that
other SNPs in ANKH (for example, rs3045) may also asso-
ciate with CC. However, in keeping with previous reports,
there was no association between SNPs in TNAP or
ENPP1 and CC [29].
ANKH encodes a multipass transmembrane protein
(ANKH) in joints and other tissues and participates in the
export of intracellular PPi [30,31]. PPi cannot diffuse across
cell membranes passively, and ANKH is the principal way
in which intracellular PPi reaches the extracellular environ-
ment. ANKH-mediated control of PPi levels regulates tis-
sue calcification and susceptibility to arthritis [30,31]. The
autosomal dominant mutations in ANKH are thought to
confer a gain in PPi transport function leading to increased
extracellular PPi levels [14,32]. Functional assays show that
the -4bpG > A transition in the 5′ UTR of ANKH reduces
intracellular PPi (a surrogate for increased transcellular PPi
export) and increases ANKH expression in vitro [14,18].
The minor alleles of rs3045 also result in lower intracellu-
lar PPi levels in vitro, providing external validity to our
finding of a possible association between this polymorph-
ism and CC [18]. These two SNPs are not in linkage dis-
equilibrium. The minor allele frequency for the -4bpG > A
transition in 5′ UTR of ANKH and rs3045 is higher in this
study than that in the multi-ethnic 1000 Genomes Project.
(See Additional file 2: Table S2 for genotype frequencies of
the selected SNPs in the 1000 Genomes Project). This may
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explain, in part, why CPPD is more common in Caucasians
than in other ethnicities.
Though not statistically significant, results from the
data suggest that rs1799945 (HFE SNP associated with
smaller iron overload), but not rs1800562 (HFE SNP as-
sociated with greater iron overload), may associate with
CC. Similar findings have been reported previously [20].
The lack of association between homozygosity for
minor allele at rs1800562 and CC may be due to a chan-
neling bias (that is, patients with hemochromatosis are
excluded from these studies).
This is the largest reported study of genetic risk fac-
tors for CC. This study has several strengths. First, the
analysis of genetic risk was adjusted for factors that as-
sociate with CC, specifically age and OA, and also for
gender, which associates with iron overload. Moreover,
correction for multiple testing was applied to reduce
the chances of a type I error. However, this study has
several caveats. First, this is a hospital-based study carried
out by reconstituting cases and controls within cohorts as-
sembled primarily to examine risk factors for knee or hip
OA within the East Midlands region of the UK. Cases with
mild to moderate large-joint OA were not included. The
study sample therefore does not resemble a community-
based population and is restricted to one area of the
country. Moreover, as more than 78% of participants had
severe large-joint OA, the results may be confounded by
their OA status. However, to minimize any confounding
and to improve the generalizability of these findings, we
have adjusted for OA at the knee and hip. Second, partici-
pants of the NOAC study did not have the same extensive
radiographic phenotyping of CC as participants of the
GOAL study. As a result, some NOAC study participants
who may have CC at distant joints without CC at the joint
to be replaced will be misclassified as ‘CC negative’ con-
trols. This misclassification is likely to minimize the gen-
etic association and does not invalidate the genetic
associations observed in this study.
Conclusions
This study validates an established genetic association with
CC and shows that this is independent of age and OA.
This study also raises the possibility that other SNPs in
ANKH associate with CC. Larger studies with greater
power are required to confirm these findings. Finally,
the findings of this study derived from a hospital-based
cohort warrant confirmation in a community-based
population including cases with mild to moderate dis-
ease and in other countries.
Table 3 Linkage disequilibrium between the genotyped single-nucleotide polymorphisms in ankylosis human
(ANKH) gene
Locus 1 Locus 2 D′ r2
rs39968 rs3045 0.746 0.028
rs39968 rs875525 0.268 0.011
rs39968 −4bpG > A 5′ UTR 0.076 0.001
rs3045 rs875525 0.826 0.226
rs3045 −4bpG > A 5′ UTR 0.625 0.004
rs875525 −4bpG > A 5′ UTR 0.448 0.006
5′ UTR, 5′ untranslated region.
Table 4 Association between chondrocalcinosis and single-nucleotide polymorphisms in the combined dataset
Common
allele
Rare
allele
MAF, % ORGENOTYPE
(95% CI)
P aORGENOTYPE
(95% CI)
P
CC+ CC−
−4bpG > A 5′ UTR G:G A:A 10.6 8.1 1.36 (1.12-1.65) 0.002 1.39 (1.14-1.69) 0.001
rs3045 T:T C:C 12.4 9.9 1.29 (1.08-1.55) 0.006 1.31 (1.09-1.58) 0.005
rs39968 C:C T:T 28.8 30.8 0.91 (0.80-1.04) 0.155 0.91 (0.80-1.04) 0.156
rs875525 C:C T:T 28.1 25.0 1.18 (1.03-1.34) 0.014 1.18 (1.03-1.35) 0.015
rs1800562 G:G A:A 8.3 7.6 1.10 (0.89-1.36) 0.386 1.13 (0.91-1.40) 0.273
rs1799945 C:C G:G 16.9 14.6 1.19 (1.02-1.39) 0.032 1.18 (1.00-1.38) 0.047
5′ UTR, 5′ untranslated region; aORGENOTYPE, adjusted genotype odds ratio; CC, chondrocalcinosis; CI, confidence interval; MAF, minor allele frequency; ORGENOTYPE,
genotype odds ratio.
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Additional files
Additional file 1: Table S1. Genotypes frequencies of ankylosis human
(ANKH) and high ferritin (HFE) single-nucleotide polymorphisms (SNPs) in
Genetics of Osteoarthritis and Lifestyle (GOAL) and Nottingham Osteoarthritis
Case-Control (NOAC) studies.
Additional file 2: Table S2. Published minor allele frequency (MAF) of
selected single-nucleotide polymorphisms (SNPs) from the 1000
Genomes Project phase 1. Genotype data from 1,094 individuals from
across the world (http://www.1000genomes.org/node/506).
Abbreviations
5′ UTR: 5′ untranslated region; ANKH: ankylosis human; BMI: body mass
index; CC: chondrocalcinosis; CCAL (1 or 2): chondrocalcinosis (1 or 2) gene;
CI: confidence interval; CPP: calcium pyrophosphate crystal; CPPD: calcium
pyrophosphate crystal deposition; ENPP1: ectonucleotide pyrophosphatase 1;
GOAL: Genetics of Osteoarthritis and Lifestyle; HFE: high ferritin; HWE: Hardy-
Weinberg equilibrium; MCPJ: metacarpophalangeal joint; NOAC: Nottingham
Osteoarthritis Case-Control; OA: osteoarthritis; ORGENOTYPE: genotype odds
ratio; PPi: pyrophosphate; SD: standard deviation; SNP: single-nucleotide
polymorphism; TNAP: tissue non-specific alkaline phosphatase.
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